Good morning Senator Specter, Senator Harkin, and Members of the Subcommittee. I am Richard Klausner, Director of the National Cancer Institute (NCI), and today I am presenting to you, for the first time, the completed NCI report estimating thyroid doses of Iodine-131 (I-131) received by Americans as a result of atmospheric nuclear bomb tests conducted at the Nevada Test Site. This study was co...

INTRODUCTION Given the shorter half-life of cesium-131 (Cs-131) compared to iodine-125 (I-125), we hypothesized that initial PSA outcomes may differ. We compare initial PSA outcomes in men undergoing Cs-131 prostate brachytherapy to men treated with I-125. PATIENTS AND METHODS The first post-treatment PSA (obtained 3-6 months after the procedure) was compared in patients undergoing I-125 pros...

ARD1 is present in various species and has several variants derived from alternative splicing of mRNA. Previously, we reported differential biological functions and cellular distributions of mouse ARD1 (mARD1) variants. However, in comparison to mARD1 variants, human ARD1 (hARD1) variants have been rarely studied. In this study, we characterized a hARD1 variant, hARD1(131) and investigated its ...

The effect of intravenous injection of beryllium nitrate to adult female Albino rats primed with Liv.52 and to non-primed rats has been studied on various hematological parameters after 2, 10 and 30 days of such injection. There was a significant decrease in RBC count, Hb%, neutrophils, blood sugar, alkaline phosphatase, globulin and total protein values with the administration of beryllium nit...

INTRODUCTION Radioactive iodine has been used for more than 50 years for the treatment of thyroid diseases. Differentiated thyroid cancers have the ability to trap iodine. Therefore, radioiodine can be used both diagnostically and therapeutically. In the follow-up of patients, it is critical to interpret radioiodine scans correctly. CASE PRESENTATION Non-physiological Iodine-131 (I-131) extra...

UNLABELLED Patients with differentiated thyroid carcinoma (DTC) are treated with (131)I therapy after total thyroidectomy or surgical resection of recurrent tumor. However, some recurrent DTC lesions are not iodine-avid, which affects further treatment planning. The aim of this study was to evaluate the clinical benefit of (18)F-FDG PET/CT performed concurrently with (131)I therapy in DTC patie...

OBJECTIVE To compare the efficacy of interstitial laser photocoagulation (ILP) with radioiodine in hot thyroid nodules. DESIGN Thirty consecutive outpatients with subclinical or mild hyperthyroidism and a scintigraphically solitary hot nodule with extraglandular suppression were randomized to either one ILP session or one radioiodine ((131)I) dose. METHODS ILP was performed under continuous...